Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Taisho Pharmaceutical Holdings
Thumbnail
October 16, 2020

Small Galapagos setback prompts a bigger loss of sentiment

A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.

Thumbnail
March 25, 2020

Making sense of Covid-19 treatment approaches

IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.

Article image
Vantage logo
March 19, 2020

First clinical data show biopharma the way against Covid-19

Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.

Article image
Vantage logo
March 18, 2020

A Covid-19 treatment plan slowly emerges

Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.

Article image
Vantage logo
January 07, 2019

Japanese biopharma rules mid-cap returns

Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?

Article image
Vantage logo
December 19, 2018

In, out, in, out, Glaxo shakes consumer health about

Earlier this year Glaxosmithkline looked to be going all-in for consumer health domination, but today it moved to leave the space entirely and focus on the thing that…

Article image
Vantage logo
October 10, 2018

Mid-cap investors see Eastern promise in the third quarter

Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…

Article image
Vantage logo
July 04, 2018

Mid and small caps provide another rocky ride in the second quarter

Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.

Article image
Vantage logo
July 04, 2018

Mid and small caps provide another rocky ride in the second quarter

Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.

Vantage logo
March 20, 2017

ACC – Jardiance heart benefit looks like a class effect

Vantage logo
September 12, 2016

Astra and Lexicon provide the good news in diabetes

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.